Source comparison
BPC-157 Leaky Gut Complete Guide 2026: Comparison Table
Before initiating any peptide protocol, understanding how BPC-157 compares to other gut-healing interventions. Both pharmaceutical and supplemental. Clarifies realistic expectations and compatibility. BPC-157 (research peptide) Upregulates tight junction prote
This comparison does not assign a generated winner or score.
- Before initiating any peptide protocol, understanding how BPC-157 compares to other gut-healing interventions. Both pharmaceutical and supplemental. Clarifies realistic expectations and compatibility.
- BPC-157 (research peptide)
- Upregulates tight junction protein synthesis (ZO-1, occludin, claudin); promotes angiogenesis via VEGF; reduces inflammatory cytokines (TNF-α, IL-6)
- 7–21 days (based on preclinical models)
- Extensive preclinical data; no controlled human trials
- Mechanistically sound with strong animal model support. Lacks human RCT validation but biologically plausible for barrier repair
- L-Glutamine (5–15g daily)
- Provides substrate for enterocyte energy metabolism; supports mucosal cell turnover; may reduce permeability through metabolic support
- 2–4 weeks
- Mixed human data; some RCTs show permeability reduction in critical illness/exercise models
- Useful adjunct with low risk. Effect size modest compared to structural repair agents
- Zinc Carnosine (75–150mg daily)
- Stabilises gut mucosa; increases mucin production; reduces oxidative damage in epithelial cells
- 4–8 weeks
- Moderate. Several human studies in gastritis/NSAID injury models
- Effective for mucosal protection but doesn't directly rebuild tight junctions. Complementary rather than primary
- Butyrate (sodium/calcium salt, 300–600mg daily)
- Primary fuel source for colonocytes; enhances tight junction assembly through histone deacetylase inhibition
- 3–6 weeks
- Strong mechanistic basis; limited human permeability data
- Most effective when gut dysbiosis is corrected first. Otherwise degraded by pathogenic bacteria before reaching target cells
- Prescription anti-inflammatory biologics (e.g., anti-TNF therapy)
- Blocks inflammatory cytokines that degrade tight junctions; reduces immune-mediated epithelial damage
- 8–12 weeks
- Extensive human RCT data in IBD populations
- Gold standard for severe inflammatory gut disease but requires prescriber oversight and carries immunosuppression risks